In laboratories outside Madrid, a bold experiment on mice quietly flipped expectations about one of medicine’s deadliest diseases.
For decades, pancreatic cancer has been the diagnosis oncologists dread telling patients about. Now a Spanish team has reported results that, while still early and confined to animals, challenge the idea that this tumour is almost unstoppable.
Why pancreatic cancer terrifies doctors and patients
Pancreatic cancer rarely gives people a fair chance. Symptoms often appear late, when the disease has already spread. Many patients first arrive in hospital with vague abdominal pain, weight loss or jaundice. By then, surgery is often no longer an option.
Current treatments are tough on the body and usually offer only modest extensions of life. Standard chemotherapy can slow the disease but frequently loses effect. Newer targeted drugs have chipped away at specific weaknesses, but the tumour almost always finds a workaround.
One gene sits at the centre of this story: KRAS. In pancreatic cancer, around nine out of ten tumours carry a mutation in this gene. KRAS controls growth signals inside cells. When it goes wrong, it acts like a stuck accelerator pedal.
Drug developers have spent years trying to shut that accelerator off. Some inhibitors against certain KRAS mutations reached patients, and in a few cancers they bought extra months. With pancreatic tumours, the benefit has been short-lived. The cancer adapts, re-routes its signalling and keeps growing.
The Spanish team decided that hitting KRAS once was not enough. They chose to hit its network from three different angles at the same time.
This change in mindset underpins the new work carried out at Spain’s National Cancer Research Centre (CNIO) in Madrid, led by veteran cancer researcher Mariano Barbacid.
The Spanish triple therapy that stunned researchers in mice
Instead of relying on a single designer drug, Barbacid’s group built a three-pronged attack on the tumour’s molecular machinery. Their strategy combined:
- Daraxonrasib, an experimental KRAS inhibitor targeting the faulty gene directly
- Afatinib, an approved drug already used for some lung cancers, blocking growth factor receptors at the cell surface
- SD36, a compound designed to degrade specific proteins that help transmit KRAS signals
All three act along the same growth pathway but at different levels, from the outside of the cell down to the signalling hubs inside. The idea is simple: if the tumour can bypass one block, it might not slip past three at once.
➡️ In Siberia, the “Gate to Hell” is growing and alarming scientists
➡️ China planted so many trees in the Taklamakan Desert that it now absorbs CO2
➡️ Gardeners urged to act now for robins : the 3p kitchen staple you should put out this evening
➡️ No more dye: the new trend that hides grey hair and makes you look younger
➡️ A new Ugandan study shows chimpanzees apply insects to their wounds
In mouse models of pancreatic cancer, including three distinct and particularly tough variants, the results were striking. The combination led to complete disappearance of tumours on imaging and pathological analysis. Researchers reported no major signs of toxicity in the animals during treatment.
Even after treatment stopped, the tumours in these mice did not come back during the observation period.
That last point matters. Many targeted therapies shrink tumours at first, only for resistant pockets of cancer to bounce back later. In this study, the triple treatment seems to have shut down the disease long enough to prevent that evolutionary escape.
How attacking three “anchor points” changes the game
Scientists involved in the work use a simple picture: imagine the tumour’s growth as a heavy structure hanging from the ceiling. If one rope is cut, it might swing but stay up thanks to other supports. Cut three key ropes at once, and the structure collapses.
KRAS and its related molecules form those supports. By targeting:
| Target | Drug used | Main role in treatment |
|---|---|---|
| Mutated KRAS protein | Daraxonrasib | Directly blocks the mutant driver of cell growth |
| Growth factor receptors on the cell surface | Afatinib | Reduces incoming signals that activate KRAS pathways |
| Downstream signalling proteins | SD36 | Marks key proteins for destruction, cutting off backup routes |
By hitting these three points simultaneously, the team disrupted the tumour’s communications system. That left cancer cells unable to reroute signals or build resistance fast enough, at least in mice.
What this could mean for patients – and what still stands in the way
The images and data from the animal studies have created genuine excitement among oncology researchers. Yet those same scientists are quick to slow expectations for families facing pancreatic cancer today.
The combination has only been tested in mice. Translating this into a therapy suitable for people involves a long list of steps: toxicity studies, dose-finding trials, and checks for drug–drug interactions. Even drugs that look safe on paper can behave differently in human bodies with other illnesses and medications.
Researchers involved in the project stress that human trials are not imminent and that careful optimisation of doses and schedules is still ahead.
The team needs to assess how long patients could tolerate such an intensive triple regimen, and whether the drugs might damage healthy tissues when used together over months. Pancreatic cancer patients are often frail, so treatment intensity must be balanced with quality of life.
Beyond the pancreas: a template for stubborn tumours
Despite those uncertainties, the approach itself could have broad consequences. Many difficult-to-treat cancers, such as some lung and colorectal tumours, also rely on KRAS and similar signalling routes. A multi-target strategy tested in pancreatic models could guide combinations elsewhere.
The project also underscores another trend: public and charitable funding stepping in to support longer, riskier research. The Spanish work drew backing from the CRIS Foundation Against Cancer and the European Research Council, among others, allowing the team to pursue experiments that commercial drug developers might see as too complex at first glance.
What patients and families should know right now
People living with pancreatic cancer, or caring for someone who is, may hear about these mouse results and wonder what they can actually do today. At this stage, the triple therapy is not available outside the lab. No clinical trial is currently open for this exact combination.
Oncologists encourage patients to ask about:
- Eligibility for ongoing clinical trials, especially those testing new KRAS inhibitors
- Genetic profiling of the tumour, which may uncover targetable mutations
- Supportive care options to manage pain, nutrition and fatigue alongside treatment
While the Spanish study cannot yet change standard treatment, it does shift how doctors think about future strategies: less reliance on one “magic bullet”, and more on coordinated attacks against several weak spots at once.
Key concepts that make this breakthrough easier to follow
For non-scientists, terms like “KRAS inhibitor” or “multi-target therapy” can feel abstract. Two ideas sit at the heart of this research.
1. Oncogene addiction – Many tumours become dependent on a single faulty gene to keep dividing. KRAS is one such gene. When a cancer is “addicted” to KRAS, blocking that signal can be devastating for the tumour, at least initially.
2. Resistance pathways – Cancer cells are genetically unstable. When one route to growth is blocked, new mutations or hidden backup circuits can step in. Combining several drugs aims to cut off both the main addiction and as many backup plans as possible.
A useful way to picture this is to imagine a city facing a power cut. Shutting down one power station might not work, because the grid can rely on other stations and backup generators. Shutting several key sources at once makes recovery far harder. This is what the Spanish team tried to mimic inside a tumour.
Where this research could lead in the next decade
If future studies confirm that triple targeting is safe and effective in humans, care for pancreatic cancer could start to resemble how HIV or some forms of leukaemia are treated: with combination regimens built from the start, rather than single agents added one by one after failure.
Doctors might one day select cocktails of targeted drugs based on a patient’s tumour profile, age, liver and kidney function, and previous treatments. Some combinations might be used for a few intense months aiming for deep remission, followed by gentler maintenance therapies. Other regimens could be paired with immunotherapy, training the immune system to recognise any cells that survive the initial onslaught.
These scenarios remain hypothetical, and research setbacks are common. Even so, the work from Madrid has reopened a door many had started to close. In a field where survival statistics have barely moved for half a century, proof that complete and lasting tumour regressions are possible in animals changes what scientists feel is worth aiming for.
Originally posted 2026-02-21 16:22:32.